|Slideshows|January 6, 2017

Antipsychotics and Breast Cancer Risk

Are antipsychotics associated with an increased risk of breast cancer?

View the slides in PDF format. Also see: Schizophrenia's Lethal Infection.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

ByJoseph F. Goldberg, MD,Robert M. Post, MD

June 5th 2026

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

ByLeslie L. Citrome, MD, MPH

June 3rd 2026

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

ByKim Do, PhD,Jessica Walters

June 3rd 2026

FDA Issues CRL for CTx-1301 for Treatment of ADHD

ByJessica Walters

June 2nd 2026

Balancing Efficacy and Risk in ADHD Pharmacotherapy

ByHelene Alphonso, DO

June 1st 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Antipsychotics and Breast Cancer Risk

Related Content

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Balancing Efficacy and Risk in ADHD Pharmacotherapy

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Suicide Risk Assessment in Patients Denying Suicidal Intent

New Name, New Path for Psychiatry: The Future of the DSM